Purpose

The present study will evaluate the effects of both aging and nicotine on psychophysical tasks and electrophysiological measures. Nicotine will be administered to study participants in the form of gum that is available as an over-the-counter medication. The hypothesis is that nicotine will reverse the detrimental effects of aging on auditory processing. The proposed experiments will characterize the effects of nicotine and may eventually lead to improved treatments of hearing loss in a variety of patient populations and in healthy aging.

Conditions

Eligibility

Eligible Ages
Between 18 Years and 85 Years
Eligible Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • between 18 and 85 years of age - non-smokers with a score of 0-2 out of 10 maximum on the Fagerström index of smoking dependency - cognitive performance within two standard deviations of the CERAD mean

Exclusion Criteria

  • less than 18 or greater than 85 years of age - deafness or excessive hearing loss - smokers with a score between 3 and 10 on the Fagerström index of smoking dependency - history of psychiatric illness, neurological disorders, diabetes mellitus, renal failure, or cardiovascular disease - regular use of prescription medications (excluding oral contraceptives) - drug dependency

Study Design

Phase
N/A
Study Type
Interventional
Allocation
Randomized
Intervention Model
Crossover Assignment
Intervention Model Description
The nicotine and placebo gums will be administered in randomized, double-blind, counterbalanced fashion.
Primary Purpose
Basic Science
Masking
Double (Participant, Investigator)
Masking Description
Nicotine (6 mg) will be administered in the form of polacrilex gum that is available as an over-the-counter medication. The placebo will also be a commercially available gum that resembles the nicotine gum in flavor, size, shape, color, and texture.

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Nicotine gum
Nicotine (6 mg) will be administered in the form of polacrilex gum that is available as an over-the-counter medication
  • Other: Nicotine gum
    Nicotine (6 mg) will be administered in the form of polacrilex gum that is available as an over-the-counter medication
Placebo Comparator
Placebo gum
The placebo will also be a commercially available gum that resembles the nicotine gum in flavor, size, shape, color, and texture.
  • Other: Placebo gum
    The placebo will also be a commercially available gum that resembles the nicotine gum in flavor, size, shape, color, and texture.

Recruiting Locations

Hearing and Speech Lab
Irvine 5359777, California 5332921 92697
Contact:
Fan-Gang Zeng
9498249107
fzeng@uci.edu

More Details

Status
Recruiting
Sponsor
University of California, Irvine

Study Contact

Fan-Gang Zeng
9498249107
fzeng@uci.edu

Detailed Description

Study participants will be recruited in two age groups: young (18-28 years) and old (60-85). Each participant will participate in two psychophysical and electrophysiological test sessions. For each of the two sessions, the participant will be administered gum before the test. For one of these sessions, the gum will be polacrilex that contains 6-mg nicotine, and for the other session, the gum will be a placebo control. The study will be double-blind, meaning that neither the experimenter nor the participant will know whether the participant has received nicotine or placebo for a given session. The study has a cross-over design, meaning that all participants will receive both nicotine and placebo in separate sessions. Finally, the order of drug administration will be counterbalanced, meaning that equal numbers of participants will receive 1) nicotine in session one and placebo in session two, and 2) placebo in session one and nicotine in session two.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.